European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
For the treatment of Superficial Femoral Artery
Continues to Expand its Presence in South India
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Subscribe To Our Newsletter & Stay Updated
